Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.

Pfizer PFE / BioNTech BNTX announced that it has signed a second agreement with the US government for the supply of its mRNA-based coronavirus vaccine BNT162b2. The US government has ordered 100 million additional doses of the vaccine, bringing the total doses for the United States to 200 million.
The US government ordered 100 million cans in July with the option to purchase up to 500 million additional cans. This leaves the US government the option to secure an additional 400 million doses of BNT162b2 in the future.
The 200 million doses that will vaccinate 100 million Americans are expected to be in the U.S. government's Operation Warp Speed ​​(OWS) by July 31.
Scroll to continue with the content
display
Microsoft and Redis
Meet the fast and fully managed in-memory data store.
Don't miss the opportunity to hear the unique perspectives from Microsoft and partner specialists and learn more about Azure Cache for Redis.
LEARN MORE
The US government will pay an additional $ 1.95 billion for the second 100 million cans, just as it did for the first 100 million cans. These payments are expected to increase Pfizer / BioNTech's sales / profits over the next few quarters.
Pfizer has similar supply agreements with other governments around the world. In the EU, Pfizer / BioNTech have agreed to deliver 200 million vaccine doses to member states in 2020/2021, with the EU having the option to purchase an additional 100 million doses in 2021.
BNT162b2 is now approved for emergency / temporary / conditional use in more than 40 countries including the US, 27 EU member states, UK and Canada.
Pfizer stock is down 4.5% this year while the industry is up 0.9%.
BioNTech's shares are up 186.4% this year, compared to an industry growth of 10%.
The emergency approvals were based on data from a Phase III study announced last month that showed that BNT162b2, a two-shot vaccine, was 95% effective against COVID-19 after two weeks of administration. The study included more than 44,000 participants. The emergency / temporary approvals for the BNT162b2 were made in less than a year since companies began development. This is probably the fastest in vaccine history.
Alongside Pfizer / BioNTech, Moderna MRNA, AstraZeneca AZN / Oxford University and J&J are the main players in the COVID-19 vaccine development race.
Pfizer / BioNTech's close competitor is Moderna, whose coronavirus vaccine mRNA-1273 has been approved for emergency use in the United States and Canada. It uses the same mRNA-based technology as Pfizer / BioNTech. The candidate achieved an effectiveness rate of 94.1% in the primary effectiveness analysis.
AstraZeneca / Oxford University's potential COVID-19 vaccine candidate, AZD1222, was, on average, about 70% effective in preventing COVID-19, according to preliminary data from late-stage studies. AstraZeneca has started submitting data for early approval to regulators around the world. With the necessary approvals, the vaccine may be launched early next year.
J & J's single-dose COVID-19 vaccine candidate, JNJ-78436735, is being evaluated in the ENSEMBLE Phase III trial, which is currently about 45,000 participants. J&J expects to report preliminary efficacy data from the ENSEMBLE study by the end of January 2021. If the data are positive, J&J will file an application for EEA with the FDA in February.
While Pfizer has a Zacks Rank 3 (Hold), BioNTech has a Zacks Rank 4 (Sell).
The full list of today's Zacks # 1 Rank (Strong Buy) stocks can be found here.
Just released: Zacks' top 7 stocks for today
Experts extracted 7 stocks from the list of 220 Zacks Rank # 1 Strong Buys that have outperformed the market more than twice, with an astonishing average gain of + 24.4% per year.
These 7 were chosen for their superior potential for an immediate outbreak.
Check out these time sensitive tickers now >>

Would you like the latest recommendations from Zacks Investment Research? Today you can download 7 Best Stocks for the next 30 days. Click here to get this free report

AstraZeneca PLC (AZN): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Stock Research Report

Moderna, Inc. (MRNA): Free Stock Research Report

BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research
In this article
PFE
-0.45%
BNTX
-3.10%
AZN
-0.51%
MRNA
-5.33%

You should check here to buy the best price guaranteed products.

Last News

OAN host calls for mass executions of those responsible for 'overthrowing' Trump

Mariah Carey, Sarah Jessica Parker, and more show support to Britney Spears during conservatorship trial

United Airlines Just Changed the Most Annoying Thing About Basic Economy Fares

Famous QAnon Couple Featured In Documentaries Arrested In Capitol Attack

Pelosi announces House Select Committee to investigate the Jan. 6 Capitol attack

Julia Roberts' Husband Danny Moder Shares Rare Video of Son Henry on His Birthday